Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
Dynamic Chart
1 day-0.66%
3 months+1.89%
6 months+1.28%
Current year+97.79%
More quotes
Current year
29.73
Extreme 29.73
69.75
1 year
14.52
Extreme 14.52
69.75
3 years
11.81
Extreme 11.805
69.75
5 years
11.81
Extreme 11.805
146.30
10 years
11.81
Extreme 11.805
146.30
More quotes
Director TitleAgeSince
Chief Tech/Sci/R&D Officer - 21-07-31
Chief Tech/Sci/R&D Officer 50 22-09-30
Investor Relations Contact - 06-08-31
Manager TitleAgeSince
Director/Board Member 56 19-05-21
Director/Board Member - Jun. 05
Director/Board Member - Jun. 05
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.66%-.--% - - 2.83B
-2.07%-1.46%+8.44%-28.35%47.07B
+0.25%+2.03%+13.35%-6.38%43.64B
+1.51%+7.12%+48.36%+44.19%34.71B
-0.20%-0.31%+33.24%-24.84%30.52B
+4.08%-9.20%-37.18%-83.26%26.59B
-1.03%+4.30%+11.78%+9.08%24.48B
+0.01%+0.75%+56.66%+72.44%15.35B
+0.70%+2.03%+2.21%-43.65%11.86B
-0.57%+8.19%+26.67%+90.65%11.03B
Average +0.20%+0.69%+18.17%+3.32% 27.25B
Weighted average by Cap. +0.17%+0.51%+16.98%-5.03%
See all sector performances
2022 2023
Net sales 278M 310M 238M 265M
Net income -151M -168M -190M -211M
Net Debt - -
More financial data * Estimated data
Logo MorphoSys AG
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Employees
464
Calendar
More about the company

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW